In Vitro Investigation of the Effects of Cape Contribution to Chemotherapeutic Drug Treatment on the Neuroblastoma Cell Line (SH SY- 5Y) on the Inflammatory Process
Öz
Anahtar Kelimeler
Destekleyen Kurum
Proje Numarası
Kaynakça
- Referans 1. Pastor ER, Mousa SA. Current management of neuroblastoma and future direction. Critical reviews in oncology/hematology. 2019;138:38-43.
- Referans2. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526(7575):700-4.
- Referans3. Jin Z, Lu Y, Wu Y, Che J, Dong X. Development of differentiation modulators and targeted agents for treating neuroblastoma. European Journal of Medicinal Chemistry. 2020:112818.
- Referans4. Ackermann S, Cartolano M, Hero B, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018;362(6419):1165-70.
- Referans5. Brodeur GM. Spontaneous regression of neuroblastoma. Cell and tissue research. 2018;372(2):277-86.
- Referans6. Joshi S. Targeting the tumor microenvironment in neuroblastoma: recent advances and future directions. Cancers. 2020;12(8):2057.
- Referans7. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians. 2016;66(4):271-89.
- Referans8. Smith V, Foster J. High-risk neuroblastoma treatment review. Children. 2018;5(9):114.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Klinik Tıp Bilimleri
Bölüm
Araştırma Makalesi
Yazarlar
Çiğdem Karaca
*
Türkiye
Hilal Susam Şen
0000-0002-1329-1287
Türkiye
Fatma Fırat
0000-0002-1880-546X
Türkiye
Esra Aslan
0000-0002-3191-4978
Türkiye
Yayımlanma Tarihi
7 Nisan 2022
Gönderilme Tarihi
11 Mart 2022
Kabul Tarihi
6 Nisan 2022
Yayımlandığı Sayı
Yıl 2022 Cilt: 3 Sayı: 1